SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...
Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...
SCD is often promoted for people with inflammatory bowel diseases (IBD), but very few studies support its effectiveness. Over the last decade, the incidence of IBD has increased worldwide. Symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback